{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:51:42Z","timestamp":1785912702073,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR500764"],"award-info":[{"award-number":["NIHR500764"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122139","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:07:31Z","timestamp":1781737651000},"page":"122139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of adjunctive orexin receptor antagonist therapy in major depressive disorder: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"412","author":[{"given":"Samuel Izaias Dos Santos","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kotochinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellgner Fernandes Oliveira","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus Rodrigues","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandora Eloa Oliveira","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Maria Freire","family":"Fidelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima Norbu","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gonzalez","family":"Lezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122139_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/NSS.S76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant","volume":"8","author":"Anderson","year":"2016","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.jad.2026.122139_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122139_bb0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12888-025-06783-7","article-title":"The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis","volume":"25","author":"Bai","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hup.561","article-title":"Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs","volume":"19","author":"Bourin","year":"2004","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jad.2026.122139_bb0025","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.2147\/IJGM.S547865","article-title":"The pathogenesis and treatment of insomnia combined with depression","volume":"18","author":"Chang","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.jad.2026.122139_bb0030","article-title":"Hypocretin-1\/hypocretin receptor 1 regulates neuroplasticity and cognitive function through hippocampal lactate homeostasis in depressed model","volume":"11","author":"Chen","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jad.2026.122139_bb0035","first-page":"80","article-title":"Activating and sedating properties of medications used for the treatment of major depressive disorder and their effect on patient functioning","author":"Citrome","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","article-title":"Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder","volume":"20","author":"Connor","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122139_bb0045","series-title":"EU-CTR 2020-000337-40 - NCT04533529","year":"2026"},{"issue":"Suppl. 16","key":"10.1016\/j.jad.2026.122139_bb0050","first-page":"27","article-title":"Daytime sleepiness and insomnia as correlates of depression","volume":"65","author":"Fava","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jamapsychiatry.2023.5060","article-title":"Components and delivery formats of cognitive behavioral therapy for chronic insomnia in adults","volume":"81","author":"Furukawa","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jad.2026.122139_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2022.101597","article-title":"Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis","volume":"62","author":"Hertenstein","year":"2022","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.jad.2026.122139_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41398-024-03087-4","article-title":"Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review","volume":"14","author":"Kishi","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0080","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","author":"Komossa","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2026.122139_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1190415","article-title":"Residual insomnia in major depressive disorder: a systematic review","volume":"14","author":"Kwa\u015bny","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115527","article-title":"Predictors of cognitive behavioral therapy for insomnia (CBT-I) effects in insomnia with major depressive episode","volume":"329","author":"Maruani","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.122139_bb0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/pcn.13811","article-title":"Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"79","author":"Maruki","year":"2025","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2026.122139_bb0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem. Med. (Zagreb)"},{"key":"10.1016\/j.jad.2026.122139_bb0105","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/s41380-024-02846-5","article-title":"Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial","volume":"30","author":"Mesens","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jad.2024.12.008","article-title":"Efficacy of orexin antagonists for the management of major depressive disorder: a systematic review of randomized clinical trials","volume":"372","author":"Meshkat","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122139_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jad.2026.122139_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","article-title":"Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials","volume":"133","author":"Moline","year":"2021","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.jad.2026.122139_bb0125","series-title":"NCT04532749","year":"2025"},{"key":"10.1016\/j.jad.2026.122139_bb0130","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2026.122139_bb0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14252","article-title":"Chronic insomnia, REM sleep instability and emotional dysregulation: a pathway to anxiety and depression?","volume":"34","author":"Riemann","year":"2025","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.jad.2026.122139_bb0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","article-title":"Efficacy and safety of Seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study","volume":"24","author":"Savitz","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122139_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euroneuro.2025.03.007","article-title":"Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: a double-blind, placebo-controlled, randomized phase 2a study","volume":"95","author":"Schmidt","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122139_bb0155","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2026.122139_bb0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2215-0366(24)00222-0","article-title":"Global Burden of Disease 2021: mental health messages","volume":"11","author":"The Lancet Psychiatry","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122139_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.copsyc.2019.11.004","article-title":"Insomnia and depression: clinical associations and possible mechanistic links","volume":"34","author":"Vargas","year":"2020","journal-title":"Curr. Opin. Psychol."},{"key":"10.1016\/j.jad.2026.122139_bb0170","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1017\/S0033291722001246","article-title":"Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis","volume":"52","author":"Yan","year":"2022","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2026.122139_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104532","article-title":"Sleep disorders and non-sleep circadian disorders predict depression: a systematic review and meta-analysis of longitudinal studies","volume":"134","author":"Zhang","year":"2022","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:26:24Z","timestamp":1785911184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726009912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S0165032726009912"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122139","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of adjunctive orexin receptor antagonist therapy in major depressive disorder: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122139"}}